Advertisement

Drug Safety

, Volume 41, Issue 10, pp 979–980 | Cite as

Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone

  • Ingrid A. Binswanger
  • Jason M. Glanz
Commentary

Extended-release (ER) injectable naltrexone (Vivitrol®) is a monthly injection approved for the treatment of opioid use disorder in the US. Other treatments for opioid use disorder include opioid agonists or partial agonists such as methadone and buprenorphine-containing products (e.g. buprenorphine-naloxone). As an opioid antagonist, naltrexone blocks the euphoric effects of opioids and may reduce the risk of opioid overdose once individuals are successfully induced into treatment [1]. However, paradoxically, the risk of opioid overdose may increase if individuals try to challenge the opioid blockade associated with naltrexone [2]. Two recent studies raise concerns about the susceptibility to opioid overdose associated with ER injectable naltrexone. In a randomized trial (n =570) comparing the effectiveness of buprenorphine-naloxone with ER injectable naltrexone, 15 individuals had 18 overdose events in the ER injectable naltrexone arm, compared with 8 individuals who had 10 overdose...

Notes

Compliance with Ethical Standards

Funding

Drs. Binswanger and Glanz are supported by the National Institute on Drug Abuse of the National Institutes of Health under award number R01DA042059. The National Institutes of Health did not contribute to the conception or writing of this commentary, or the decision to submit this article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of interest

Ingrid A. Binswanger is employed by the Colorado Permanente Medical Group and receives royalties from Uptodate. Jason M. Glanz has no conflicts of interest that are directly relevant to the content of this commentary.

References

  1. 1.
    Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018.  https://doi.org/10.1038/s41380-018-0094-5 (Epub 22 Jun 2018).CrossRefPubMedGoogle Scholar
  2. 2.
    Jarvis BP, DeFulio A, Long L, Holtyn AF, Umbricht A, Fingerhood M, et al. Factors associated with using opiates while under extended-release naltrexone blockade: a descriptive pilot study. J Subst Abuse Treat. 2018;85:56–60.CrossRefGoogle Scholar
  3. 3.
    Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.CrossRefGoogle Scholar
  4. 4.
    Kelty E, Hulse G. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Pol. 2017;46:54–60.CrossRefGoogle Scholar
  5. 5.
    Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–209.CrossRefGoogle Scholar
  6. 6.
    Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.CrossRefGoogle Scholar
  7. 7.
    Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther. 1985;232(2):439–44.PubMedGoogle Scholar
  8. 8.
    Unterwald EM, Anton B, To T, Lam H, Evans CJ. Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone. Neuroscience. 1998;85(3):897–905.CrossRefGoogle Scholar
  9. 9.
    Saucier R, Wolfe D, Dasgupta N. Review of case narratives from fatal overdoses associated with injectable naltrexone for opioid dependence. Drug Saf. 2018.  https://doi.org/10.1007/s40264-018-0653-3 (Epub 20 Mar 2018).CrossRefPubMedGoogle Scholar
  10. 10.
    Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abuse. 2015;36(2):240–53.CrossRefGoogle Scholar
  11. 11.
    Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–58.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Institute for Health Research, Kaiser Permanente ColoradoDenverUSA
  2. 2.Colorado Permanente Medical GroupAuroraUSA
  3. 3.Division of General Internal MedicineUniversity of Colorado School of MedicineAuroraUSA
  4. 4.Colorado School of Public HealthAuroraUSA

Personalised recommendations